<!DOCTYPE HTML>

<html>
	<head>
		<title>Pharmaceutical Industry in China</title>
		<meta charset="utf-8" />
		<meta name="viewport" content="width=device-width, initial-scale=1, user-scalable=no" />
		<link rel="stylesheet" href="assets/css/main.css" />
	</head>
	<body class="is-preload">

		<!-- Wrapper -->
			<div id="wrapper">

				<!-- Main -->
					<div id="main">
						<div class="inner">

							<!-- Header -->
					

							<!-- Content -->
								<section>
									<header class="main">
										<h1 id="h1 top">Case Study</h1>
									</header>

									<span class="image main"><img src="images/cover.gif" alt="" /></span>


									<hr class="major" />
									<h2 id="c1">Case Study - Sino Biopharmaceutical</h2>

									

									<h3>Company Overview</h3>
									<p style="text-align:justify"><span class="image right"><img src="images/cb1.jpg" alt="" /></span>Sino biopharma is an industry leader for generic drugs and specialize in liver related diseases. Through its continuous reformation and innovation in medical, pharmaceutical, and health fields, it has grown in size with more than 20 shareholding companies.  <br/><br/>
									</p>
									<p style="text-align:justify"><span class="image left"><img src="images/sino.png" alt="" /></span>
										It has a professional promotion team consisting of more than 10,000 employees, and nearly 1,000 kinds of products, covering all types of medical institutions at all levels across the country. We have launched more than 30 products with annual sales revenue of over 100 million CNY. Especially in the field of liver diseases, a number of major products have annual sales revenue exceeding 1 billion CNY, accounting for 24% in the overall sales income of the liver disease market in China.



Sino Boppharama has a competitive drug portfolio and robust R&D pipeline, with R&D spending percentage topping peers, as seen from the graph above.  </p>

<p style="text-align:justify">Find out more at Sino Biopharma’s website at: <a target="_blank" href=http://www.sinobiopharm.com/en/#/>http://www.sinobiopharm.com/en/#/</a><br/>

 Find out more about Sino Biopharma’s industry competitiveness within R&D, manufacturing, and distribution:</p>
<center><iframe width="560" height="315" src="https://www.youtube.com/embed/ox8GuaeEybg" frameborder="0" allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen></iframe></center>
<br/><br/>
<h3>Recent Growth Catalysts</h3>

<p style="text-align:justify">Sino Biopharma’s competitive edge is developed by three main pillars, including a diverse R&D portfolio, strength in product distribution and rollout, participating in national reimbursement schemes, and having first to market advantages. These competitive edges has enabled Sino Biopharma to have higher margins, fewer industry competition, and a longer market shelf life.</p>
<span class="image fit"><img src="images/rd.png" alt="" /></span>
<br/>
<h3>Historical Performance Highlight</h3>
<p><span class="image left"><img src="images/sino_h.png" alt="" /></span>
	<b style="color:forestgreen">2010:</b> Admitted into HSI Consumer Goods and HSI Small Cap constituent stock<br/>
	<b style="color:cornflowerblue">2014:</b> Acquired Karoliska Development and became largest stakeholder<br/>
	<b style="color:gold">2015:</b> Acquired LifeBond, an Israel based medical device company, became 2nd  largest shareholder<br/>
	<b style="color:peru">2017: </b> Acquired 42% stake of Qingdao Chia Tai<br/>
	<b style="color:red">2018: </b> 1 Government Policy on GPO (Group purchasing regulation) impact on pharma industry 2 Acquired 24% of Beijing Tide 3 Admitted into HSI Constituent stock<br/>
</p>


									<hr class="major" />
									<h2 id="c2">Case Study - Hengrui Medicine</h2>
									<h3>Company Overview</h3>
									<p>Hengrui Medicine is a pharmaceutical company based in China focusing on research, development, manufacturing, and commercialization of innovative and high-quality healthcare products.</p>


									<p style="text-align:justify"><span class="image right"><img src="images/hr.png" alt="" /></span>
<ul>
																<li>Founded in 1970</li>
																<li>Market capitalization: USD 50 billion</li>
																<li>Employee: 24,700</li>
																		<li>Forbes’s top 100 world’s most innovative company </li>
																<li>Largest antitumor drug manufacturer in China (over 12% of market share)</li>
																<li>Key products: antitumor, surgical, endocrine, cardiovascular and anti-infective drugs</li>
															</ul>
									 </p>

<h3>Brand Pharma Valuation 
</h3>
<div class="row">

								<div class="col-4 col-12-medium">
												<h5>Highest R&D spender in China 
</h5>
												<span class="image fit"><img src="images/hr1.png" alt="" /></span>
											</div>
											<div class="col-4 col-12-medium">
												<h5>Strong sales force ensures monetization
</h5>
												<span class="image fit"><img src="images/hr2.png" alt="" /></span>
											</div>
											<div class="col-4 col-12-medium">
												<h5>Revenue breakdown by therapeutic area 
</h5>
												<span class="image fit"><img src="images/hr3.png" alt="" /></span>
											</div>
										</div>

<br/>
<h3>From generic pharma to brand pharma </h3>
<h4>From fast-follow to innovative drugs </h4>
<span class="image fit"><img src="images/hr4.png" alt="" /></span>
<h4>Company share price history </h4>
<p><span class="image left"><img src="images/hr5.png" alt="" /></span>
	<b style="color:black">Phase 1: 1997-2008</b> <br/>Focused on fast follow, aiming to replace foreign products<br/>
	<b style="color:black">Phase 2: 2008-2014</b> <br/>Commitment to innovative R&D (me better) and “go global” <br/>
	<b style="color:black">Phase 3: 2014-2018</b> <br/>Market generic drugs to overseas market; focus on genuinely innovative drugs  <br/>
</p>

								</section>
								<section>
									<header class="major">
										<h2>Analysis</h2>
									</header>
									<div class="posts">
										<article>
											<a href="io.html" class="image"><img src="images/cover.png" alt="" /></a>
											<h3>Industry Overview</h3>
											<p>Customer Segmentation | Overview of China Healthcare Industry | Overview of China Drug Industry</p>
											<ul class="actions">
												<li><a href="io.html" class="button primary">More</a></li>
											</ul>
										</article>
										<article>
											<a href="icv.html" class="image"><img src="images/ivc_c.jpg" alt="" /></a>
											<h3>Industry Value Chain</h3>
											<p>The Life of a Drug | 
												Demystifying R&D + Drug Registration | 
												Supply Chain and Major Players (Competitive Landscape) </p>
											<ul class="actions">
												<li><a href="ivc.html" class=" button primary">More</a></li>
											</ul>
										</article>
										<article>
											<a href="sf.html" class="image"><img src="images/sf_c.jpg" alt="" /></a>
											<h3>Success Factor</h3>
											<p>Policy & Regulation Support | 
												Distribution Channel</p>
											<ul class="actions">
												<li><a href="sf.html" class="primary button">More</a></li>
											</ul>
										</article>
										
										<article>
											<a href="cs.html" class="image"><img src="images/cs_c.jpg" alt="" /></a>
											<h3>Case Study</h3>
											<p>Company 1 - Sino | Company 2 - Henrui</p>
											<ul class="actions">
												<li><a href="cs.html" class="primary button">More</a></li>
											</ul>
										</article>
										<article>
											<a href="ft.html" class="image"><img src="images/ft_c.jpg" alt="" /></a>
											<h3>Future Trend</h3>
											<p>Regulatory and Policy: Centralized Procurement | National Reimbursement Drug List (NRDL)</p>
											<ul class="actions">
												<li><a href="ft.html" class="primary button">More</a></li>
											</ul>
										</article>
										<article>
											<a href="ij.html" class="image"><img src="images/ij_c.jpg" alt="" /></a>
											<h3>Glossary</h3>
											<p>Industrial Jardon | Interesting Video</p>
											
											<ul class="actions">
												<li><a href="ij.html" class=" primary button">More</a></li>
											</ul>
										</article>
									</div>
								</section>

						</div>
					</div>

				<!-- Sidebar -->
					<div id="sidebar">
						<div class="inner">

							<!-- Menu -->
								<nav id="menu">
									<header class="major">
										<h2>Menu</h2>
									</header>
									<ul>
										<li><a href="index.html#h1">Homepage</a></li>
										<li>
											<span class="opener">Industry Overview</span>
											<ul>
												<li><a href="io.html#io1">Custom Segmentation</a></li>
												<li><a href="io.html#io3">Overview of China Healthcare Industry</a></li>
												<li><a href="io.html#io4">Overview of China Drug Industry</a></li>
											</ul>
										</li>
										<li>
											<span class="opener">Industry Value Chain</span>
											<ul>
												<li><a href="ivc.html#ivc1">The Life of a Drug</a></li>
												<li><a href="ivc.html#ivc2">Demystifying R&D + Drug Registration</a></li>
												<li><a href="ivc.html#ivc3">Supply Chain and Major Players </a></li>
											</ul>
										</li>
										<li>
											<span class="opener">Success Factor</span>
											<ul>
												
												<li><a href="sf.html#sf1">Policy & Regulation Support</a></li>
												<li><a href="sf.html#sf2">Distribution Channel</a></li>
											</ul>
										</li>
										

										<li>
											<span class="opener">Future Trend</span>
											<ul>
												<li><a href="ft.html#ft1">Regulatory and Policy: <br/>Centralized Procurement </a></li>
												<li><a href="ft.html#ft2">National Reimbursement Drug List (NRDL)</a></li>
											</ul>
										</li>
										
										<li>
											<span class="opener">Case Study </span>
											<ul>
												<li><a href="cs.html#c1">Company 1 - Sino</a></li>
												<li><a href="cs.html#c2">Company 2 - Henrui</a></li>
											</ul>
										</li>
										<li>
											<span class="opener">Glossary </span>
											<ul>
												<li><a href="ij.html#ij1">Industrial Jardon</a></li>
												<li><a href="ij.html#ij2">Interesting Video</a></li>
											</ul>
										</li>
									</ul>
								</nav>

							<!-- Section -->
							
								<section>
									<header class="major">
										<h2>Latest News</h2>
									</header>
									<div class="mini-posts">
										<article>
											<a target="_blank" href="https://www.economist.com/business/2019/09/28/chinas-pharmaceuticals-industry-is-growing-up" class="image"><img src="images/n1.jpg" alt="" /></a>
											<p>The Economist - China’s pharmaceuticals industry is growing up </li></p>
										</article>
										<article>
											<a target="_blank" href="https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/chinese-growth-shots-some-years-away-for-pharma-companies/articleshow/71513734.cms" class="image"><img src="images/n2.jpg" alt="" /></a>
											<p>The Economic Times - Chinese growth shot’s some years away for pharma companies </p>
										</article>
										<article>
											<a target="_blank" href="https://www.chinadaily.com.cn/a/201908/14/WS5d536f5ea310cf3e35565a93.html" class="image"><img src="images/n3.jpg" alt="" /></a>
											<p>China Daliy - Pharma companies undergoing critical transformation</p>
										</article>
										<article>
											<a target="_blank" href="https://www.pharmaceutical-technology.com/comment/china-pharmaceutical-industry-2019/" class="image"><img src="images/n4.jpg" alt="" /></a>
											<p>Pharmaceutical Technology - Characterising Eastern China’s pharmaceutical manufacturing market: Shandong and Jiangsu</li></p>
										</article>
										<article>
											<a target="_blank" href="https://www.expresspharma.in/cover-story/is-china-the-next-land-of-opportunity/" class="image"><img src="images/n5.jpg" alt="" /></a>
											<p>Express Pharma - Is China the next land of opportunity? </p>
										</article>
										
									</div>
									
								</section>

							<!-- Section -->
							
								<section>
									<header class="major">
										<h2>Get in touch</h2>
									</header>
							
									<ul class="contact">
										<li class="icon solid fa-envelope"><a href="mailto:haa300.2019@gmail.com">pharama_in_ch@gmail.com</a></li>
									
									</ul>
									
										<h2 class="major"><a href="#top">Back to Top</a></h2>
								

							<!-- Footer -->
								<footer id="footer">
									<p class="copyright">&copy; Untitled. All rights reserved. <br/> Edited by GROUP E @ Fall 2020 - GBUS3030
										<br/> Nov 28, 2019</p>
								</footer>
								
						</div>
					</div>

			</div>

		<!-- Scripts -->
			<script src="assets/js/jquery.min.js"></script>
			<script src="assets/js/browser.min.js"></script>
			<script src="assets/js/breakpoints.min.js"></script>
			<script src="assets/js/util.js"></script>
			<script src="assets/js/main.js"></script>

	</body>
</html>